Edition:
United Kingdom

Zafgen Inc (ZFGN.OQ)

ZFGN.OQ on NASDAQ Stock Exchange Global Select Market

7.82USD
8:59pm GMT
Change (% chg)

$0.05 (+0.64%)
Prev Close
$7.77
Open
$7.82
Day's High
$8.31
Day's Low
$7.80
Volume
41,103
Avg. Vol
39,633
52-wk High
$9.26
52-wk Low
$3.21

Chart for

About

Zafgen, Inc. is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company's lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including... (more)

Overall

Beta: -1.40
Market Cap(Mil.): $94.27
Shares Outstanding(Mil.): 27.48
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Zafgen Says Co Entered Into Loan And Security Agreement Providing For Term Loan With Principal Amount​ Of $20 Mln

* ZAFGEN SAYS ‍ON DEC 29, CO ENTERED INTO LOAN AND SECURITY AGREEMENT PROVIDING FOR TERM LOAN WITH PRINCIPAL AMOUNT​ OF $20 MILLION - SEC FILING Source text: [http://bit.ly/2Earwn6] Further company coverage:

05 Jan 2018

BRIEF-Zafgen Reports Strong Clinical Progress And Updates Outlook For 2018

* ZAFGEN REPORTS STRONG CLINICAL PROGRESS AND UPDATES OUTLOOK FOR 2018

05 Jan 2018

BRIEF-Zafgen reports Q3 loss per share $0.46

* Q3 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S

07 Nov 2017

BRIEF-Zafgen appoints Jeffrey Hatfield as CEO

* Zafgen appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to continue as president, appointed chief scientific officer

10 Oct 2017

BRIEF-Zafgen initiates Phase 2 clinical trial for ZGN-1061

* Zafgen initiates Phase 2 clinical trial for ZGN-1061 in patients with Type 2 diabetes Source text for Eikon: Further company coverage:

12 Sep 2017

Earnings vs. Estimates